Bristol Myers Squibb (BMY) Heads To ESMO 2026 With New Oncology Data

Bristol-Myers Squibb (NYSE:BMY) plans to present late-breaking oncology data at ESMO 2026, including new results for pumitamig. The company will also share milestone findings for izalontamab brengitecan (iza bren) that focus on next-generation cancer modalities. Updated long-term survival data for the Opdivo plus Yervoy immunotherapy combination are scheduled for disclosure at the same meeting. The ESMO 2026 data on pumitamig, iza bren and Opdivo plus Yervoy sits against a wider backdrop our...